Please assess the completion status of the following clinical trial:

Trial Title: The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years old~2. Heart Failure Reduced ejection fraction (HFrEF) of 40 or less~3. Estimated glomerular filtration rate (eGFR) \> 30milliliters(ml)/minute(min)/1.73 meter(m)2~4. Admitted to CCU by advanced heart failure service for decompensated heart failure requiring continuous hemodynamic monitoring with a pulmonary artery catheter~Exclusion Criteria:~1. Diagnosis of type 1 diabetes mellitus~2. eGFR \< 30ml/min/1.73m2~3. age \< 18 years old~4. Jehovah's witnesses~5. Diagnosis of group 1 pulmonary arterial hypertension~6. Insulin requirement above standard low dose sliding scale~7. Patients with a history of diabetic ketoacidosis (DKA)~8. Allergies to SGLT2i medications~9. History of intolerance to SGLT2i medications~10. Patients listed for cardiac transplantation or on mechanical support~11. Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGLT2i (Type: ACTIVE_COMPARATOR): Participants will be treated with a SGLT2i during their ICU stay. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
- No SGLT2i (Type: ACTIVE_COMPARATOR): Participants will not be treated with a SGLT2i during their ICU stay. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.

Based on this trial design, predict the completion outcome and termination type (if applicable).